Otsuka’s Novel Samska Gets U.S. Advisory Committee Review
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA's Cardiovascular and Renal Drugs Advisory Committee will meet June 25 to evaluate Otsuka Pharmaceutical's hyponatremia drug Samska (tolvaptan) for approval in patients with hypervolemic and euvolemic hyponatremia.